-
Interferon a-n1 (Wellferon), interferon a-n3 (Alferon), and interferon b-1b (Betaferon) were each found to have in vitro activity against a strain of the SARS coronavirus.
-
-
-
History and Goals of Antiretroviral Therapy; Clinical Trials: Recent Assessments of Various Triple Nucleoside Regimens as HAART for Treatment-Naïve HIV-Infected Patients; Lower Efficacy With Stavudine, Didanosine, and ABC Triple NRTI Regimen; Tenofovir DF (TDF)/ABC/3TC Versus EFV/ABC/3TC in Antiretroviral-naïve HIV Patients; Atlantic Study: An Assessment of d4T/ddI/3TC; CLASS: Triple NRTI d4T/3TC/ZDV Versus NNRTI- and PI-based HAART; Efficacy From Trials With Quadruple PI-Sparing Therapy
-
Breast Cancer and the Use of Statins; Warnings Issued for IBS Drugs; FDA Actions
-
Animal Reservoirs for SARS; SARS Screening Identifies TB Cases Instead; Measles Outbreak Among Chinese Adoptees; Recovery of Vaccinia after Smallpox Inoculation; Risk of Hepatitis A in Travelers to Developing Countries
-
The following summary of selected abstracts from 3 meetings will be published in multiple parts. The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) met in Chicago September 14-17, 2003. The Infectious Disease Society of America (IDSA) met in San Diego October 9-12, 2003. The American Society of Tropical Medicine and Hygiene met in Philadelphia December 3-7, 2003.
-
Mupirocin application to the nose of hospitalized Staphylococcus aureus carriers did not decrease the incidence of nosocomial S aureus infection, but it did delay its appearance.
-
Almost 1 in 20 Candida species isolated were misidentified by clinical laboratories; these errors have potential for engendering adverse clinical outcomes. C glabrata was the species most frequently misidentified.
-
The primary therapeutic goals when initiating therapy in patients infected with HIV are maximal and long-lasting suppression of viral replication, maintenance or restoration of immunologic function, improvement of quality of life, and reduction of HIV-related morbidity and mortality.(1) Highly active antiretroviral therapy (HAART) using combinations of antiretroviral agents has been shown to achieve these goals to a significant degree and reduce morbidity and mortality in the population of HIV-infected patients.
